221 related articles for article (PubMed ID: 33933288)
1. [A standardized medical report template for CAR T-Cell therapy patients: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Broussais F; Vasseur A; Karam M; Chaillou D; Pereira M; Yakoub-Agha I; Raus N
Bull Cancer; 2021 Dec; 108(12S):S82-S86. PubMed ID: 33933288
[TBL] [Abstract][Full Text] [Related]
2. [Reporting data of patients receiving CAR T cell therapy into the EBMT registry: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Vasseur A; Karam M; Chaillou D; Colonnese E; Dantin C; Latiere C; Meziane Y; Pereira M; Yakoub-Agha I; Chabannon C; Raus N
Bull Cancer; 2020 Dec; 107(12S):S178-S184. PubMed ID: 31831153
[TBL] [Abstract][Full Text] [Related]
3. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
[TBL] [Abstract][Full Text] [Related]
4. [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France].
Broussais F; Bay JO; Boissel N; Baruchel A; Arnulf B; Morschhauser F; Robin M; Guepin GR; Moreau P; Gandemer V; Manier S; Leguay T; Nguyen Quoc S; Schwartzmann A; Houot R; Le Gouill S
Bull Cancer; 2021 Oct; 108(10S):S143-S154. PubMed ID: 34920797
[TBL] [Abstract][Full Text] [Related]
5. [The care process of patient receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Beauvais D; Andrianne C; Aubrun C; Berquier M; Bole S; Caulier A; Courbon C; Delorme J; Fournier I; François G; Jaivenois MF; Le Bars L; Mussot I; Vercasson M; Wallart Brejaud A; Yakoub-Agha I; Lacroix D
Bull Cancer; 2020 Dec; 107(12S):S170-S177. PubMed ID: 32891406
[TBL] [Abstract][Full Text] [Related]
6. Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Yakoub-Agha I
Curr Res Transl Med; 2018 May; 66(2):57-58. PubMed ID: 29685843
[TBL] [Abstract][Full Text] [Related]
7. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
[TBL] [Abstract][Full Text] [Related]
8. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L
Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.
Bonaldo G; Montanaro N; AlbertoVaccheri ; Motola D
Eur J Clin Pharmacol; 2021 Aug; 77(8):1225-1234. PubMed ID: 33608749
[TBL] [Abstract][Full Text] [Related]
10. [Follow-up logbook of patients receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Berquier M; Cherel L; Clerc Renaud D; Hospital Gustems C; Wallart Brejaud A; Yakoub-Agha I; Beauvais D
Bull Cancer; 2021 Dec; 108(12S):S39-S44. PubMed ID: 33992416
[TBL] [Abstract][Full Text] [Related]
11. [Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Yakoub-Agha I; Ferrand C; Chalandon Y; Ballot C; Castilla Llorente C; Deschamps M; Gauthier J; Labalette M; Larghero J; Maheux C; Moreau AS; Varlet P; Pétillon MO; Pinturaud M; Rubio MT; Chabannon C
Bull Cancer; 2017 Dec; 104(12S):S43-S58. PubMed ID: 29174320
[TBL] [Abstract][Full Text] [Related]
12. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice.
Dushenkov A; Jungsuwadee P
J Oncol Pharm Pract; 2019 Jul; 25(5):1217-1225. PubMed ID: 30890066
[TBL] [Abstract][Full Text] [Related]
14. [Quality assessment of CAR T-cell activity: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Duléry R; Lacassagne MN; Giraud C; Ader V; Beaumont JL; Carnoy S; Carpentier A; Fegueux N; Gibault-Joffe C; Guerout-Verite MA; Huynh TNP; Lewalle P; Perrin A; Plaza-Milhe S; Bonnin A; Yakoub-Agha I; Contentin N
Bull Cancer; 2020 Dec; 107(12S):S193-S201. PubMed ID: 33187683
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy with CAR-T cells in paediatric haematology-oncology].
Mirones I; Moreno L; Patiño-García A; Lizeaga G; Moraleda JM; Toribio ML; Pérez-Martínez A; ;
An Pediatr (Engl Ed); 2020 Jul; 93(1):59.e1-59.e10. PubMed ID: 32107177
[TBL] [Abstract][Full Text] [Related]
16. [Improving diagnosis coding in the ProMise database: Guidelines of the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Polge E; Bourgue F; Cuvelier M; Pires B; Hugon N; Laurent N; Leclerc N; Leroux S; Le Bars L; Marion S; Meziane Y; Moukhtari L; Renault M; Peffault de Latour R; Yakoub-Agha I; Raus N
Bull Cancer; 2016 Nov; 103(11S):S213-S219. PubMed ID: 27842859
[TBL] [Abstract][Full Text] [Related]
17. Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health.
Raimond V; Kaltenbach E; Adam C; Lazzarotto S; Le Galès C; Perrier L; Wittwer J
Bull Cancer; 2021 Dec; 108(12):1162-1169. PubMed ID: 34629167
[TBL] [Abstract][Full Text] [Related]
18. [HLA coding in ProMISe: Guidelines from the Francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Raus N; Faucher C; Kennel A; Pereira M; Veron C; Yakoub-Agha I; Loiseau P
Bull Cancer; 2017 Dec; 104(12S):S65-S70. PubMed ID: 29128085
[TBL] [Abstract][Full Text] [Related]
19. [How to capture cytogenetic and molecular abnormalities into ProMISe database for hematological malignancies: Guidelines from the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Raus N; Karam M; Chebel R; Dantin C; Pereira M; Wallart A; Yakoub-Agha I; Srour M
Bull Cancer; 2020 Jan; 107(1S):S52-S61. PubMed ID: 31615645
[TBL] [Abstract][Full Text] [Related]
20. [Complications other than infections, CRS and ICANS following CAR T-cells therapy: Recommendations of the Francophone Society of bone marrow transplantation and cell therapy (SFGM-TC)].
Pochon C; Courbon C; Bay JO; Moreau AS; Paul F; Picard M; Sterin A; Tudesq JJ; Vicente C; Yakoub-Agha M; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S98-S103. PubMed ID: 34802718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]